E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Solid tumors and primary central nervous system (CNS) tumors |
|
E.1.1.1 | Medical condition in easily understood language |
A solid tumor is an abnormal tissue mass that arises from uncontrolled growth of cells and spreads locally or to other parts of the body and one that starts in brain is called a primary brain tumor |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10065147 |
E.1.2 | Term | Malignant solid tumor |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10065252 |
E.1.2 | Term | Solid tumor |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D), of entrectinib in pediatric patients (pediatrics and young adults) with relapsed or refractory solid tumors (Part A) • To evaluate efficacy of entrectinib as assessed by objective response rate (ORR) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 molecular alterations (Part B) using Response Assessment in Neuro-Oncology Criteria (RANO) and in patients with extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions (Part D) using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), as assessed by blinded independent central review (BICR)
|
|
E.2.2 | Secondary objectives of the trial |
• To describe the safety profile of entrectinib • To characterize the PK of entrectinib • To determine the duration of response (DOR), time to response (TTR), clinical benefit rate (CBR), progression-free survival (PFS), and overall survival (OS) in all enrolled patients receiving entrectinib at the RP2D • To determine the intracranial tumor response, DOR, TTR, and CNS- PFS in Parts B and D patients receiving entrectinib at the RP2D and presenting with measurable primary or secondary CNS disease at baseline, using RANO or RANO-BM, as applicable • To describe growth, puberty, neurological and neurocognitive function of patients on treatment • To evaluate the efficacy of entrectinib as assessed by ORR in all patients with NTRK1/2/3 gene fusions, regardless of study phase or cohorts using RANO for CNS tumors or RECIST v1.1 for extra-cranial tumors, as assessed by BICR • To characterize palatability and tolerability of the age-appropriate formulation
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Body surface area (BSA): Patients must have a BSA >= 0.43 m2 at the time of the study enrollment Disease status: - Phase 1 portion: Patients must have measurable or evaluable disease - Phase 2 portion: – Part B, Part D, Part C: Patients must have measurable or evaluable disease – Part E: Patients must have measurable or evaluable disease and will be assessed according to tumor type - Tumor types included below harboring NTRK1/2/3 or ROS1 gene fusions as determined locally by an appropriately validated assay performed in a Clinical Laboratory Improvement Amendments-certified or equivalently-accredited diagnostic laboratory, or centrally by a Foundation Medicine Clinical Trial Assay: o Phase 1 portion: – Part A: Relapsed or refractory extracranial solid tumors o Phase 2 portion: – Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions – Part D: Extracranial solid tumors with NTRK1/2/3 or ROS1 gene fusions - Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse - For patients enrolled via local molecular testing, an archival tumor tissue from diagnosis or, preferably, from relapsed disease is required to be submitted for independent central testing at Foundation Medicine, Inc. laboratory - Age: Male or female from birth to age < 22 years - Performance status: Lansky or Karnofsky score >= 60% and minimum life expectancy of at least 4 weeks - Prior therapy: The patient’s cancer must have no curative first-line treatment option or recurrent/refractory solid tumors and primary CNS tumors. Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment - Adequate bone marrow, liver, renal, cardiac and neurologic function - Females of childbearing potential must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation and in the following 90 days after discontinuation of study treatment - Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
|
|
E.4 | Principal exclusion criteria |
- Current participation in another therapeutic clinical trial - Known congenital long QT syndrome - Known active infections (bacterial, fungal, or viral) - Receiving Enzyme Inducing Antiepileptic Drugs within prior 14 days - All Phase 2 patients: Prior treatment with approved or investigational tyrosine receptor kinase inhibitor (TRK) or ROS1 inhibitors - Patients with NB with bone marrow space-only disease - Incomplete recovery from acute effects of any surgery prior to treatment - Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption - Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or entrectinib administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry in to this study or could compromise protocol objectives in the opinion of the Investigator and/or Sponsor
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Dose limiting toxicity of entrectinib (Part A) 2. Objective response rate (Part B)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. Day 1-28 of Cycle 1 2. Up to 30 days after last dose of study drug
|
|
E.5.2 | Secondary end point(s) |
1. Incidence and severity of adverse events, laboratory and electrocardiogram (ECG) abnormalities 2. Maximal plasma concentration (Cmax) of entrectinib 3. Time of maximal plasma concentration (Tmax) of entrectinib 4. Area under the plasma concentration vs. time curve (AUC) of entrectinib 5. Duration of response in patients with relapsed or refractory extracranial solid tumors 6. Time to response in patients with relapsed or refractory extracranial solid tumors 7. Clinical benefit rate in patients with relapsed or refractory extracranial solid tumors 8. Progression-free survival in patients with relapsed or refractory extracranial solid tumors 9. Intracranial tumor response in Parts B and D patients presenting with measurable primary or secondary CNS disease at baseline 10. Duration of response in Parts B and D patients presenting with measurable primary or secondary CNS disease at baseline 11. Time to response in Parts B and D patients presenting with measurable primary or secondary CNS disease at baseline 12. CNS- Progression-free survival in Parts B and D patients presenting with measurable primary or secondary CNS disease at baseline 13. Overall survival for all patients 14. Objective response rate in all patients 15. Acceptability and palatability assessment for capsules and age-appropriate dosage form
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Up to 30 days after last dose and every 3 months until death 2-4. Cycle 1 Day 1 pre-dose and at 1, 2, 4, 6, and 24 hours post-dose; Cycle 1 Days 8, 15 and 22 pre-dose; on Cycle 2 Day 1 pre-dose and at 1, 2, 4, 6, and 24 hours post-dose; and on Day 1 of every cycle thereafter pre-dose 5- 14. Up to 30 days after last dose of the study drug and every 3 months until death 15. Day 1 of Cycle 1
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Determine Maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D), of entrectinib in paediatric patients. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 12 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
France |
Germany |
Italy |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 11 |
E.8.9.2 | In all countries concerned by the trial months | 1 |